MMCM
BSX icon

Murphy & Mullick Capital Management’s Boston Scientific BSX Stock Holding History

Murphy & Mullick Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.12K Sell
120
-235
-66% -$12.8K ﹤0.01% 545
2026
Q1 		$22.3K Sell
355
-210
-37% -$16.8K 0.02% 383
2025
Q4 		$53.9K Buy
565
+310
+122% +$30.4K 0.04% 276
2025
Q3 		$25K Buy
255
+170
+200% +$17.6K 0.02% 359
2025
Q2 		$8.92K Buy
85
+75
+750% +$7.59K 0.01% 473
2025
Q1 		$1.01K Sell
10
-70
-88% -$7.05K ﹤0.01% 613
2024
Q4 		$7.15K Buy
+80
New +$7.04K 0.01% 474

Other funds holding BSX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Murphy & Mullick Capital Management's BSX Position: Q2 2026 in Review

Murphy & Mullick Capital Management reduced its Boston Scientific (BSX) stake by 66% in Q2 2026, selling an estimated $12.8K and leaving 120 shares worth $5.12K. The position accounts for ﹤0.01% of the portfolio, ranked #545.

Murphy & Mullick Capital Management first reported a position in BSX in Q4 2024 and has held it in 7 quarters since. The position peaked at $53.9K in Q4 2025. 1,474 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Murphy & Mullick Capital Management held 120 shares of Boston Scientific worth $5.12K as of Q2 2026.
  • Murphy & Mullick Capital Management sold 235 Boston Scientific shares in Q2 2026, an estimated $12.8K.
  • Boston Scientific made up ﹤0.01% of Murphy & Mullick Capital Management's portfolio in Q2 2026, its #545 holding.
  • Murphy & Mullick Capital Management first reported a position in Boston Scientific in Q4 2024 and has held it in 7 quarters since.
  • Murphy & Mullick Capital Management's Boston Scientific position peaked at $53.9K in Q4 2025.
  • 1,474 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.